RT Journal Article
SR Electronic
T1 Domperidone, a new dopamine antagonist
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 457
OP 461
VO 135
IS 5
A1 M. C. Champion
A1 M. Hartnett
A1 M. Yen
YR 1986
UL http://www.cmaj.ca/content/135/5/457.abstract
AB Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.